| 1.38 -0.03 (-2.13%) | 08-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.65 |
1-year : | 1.78 |
| Resists | First : | 1.41 |
Second : | 1.52 |
| Pivot price | 1.38  |
|||
| Supports | First : | 1.24 |
Second : | 1.03 |
| MAs | MA(5) : | 1.39 |
MA(20) : | 1.36 |
| MA(100) : | 1.26 |
MA(250) : | 1.31 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 46.7 |
D(3) : | 60 |
| RSI | RSI(14): 51.5 |
|||
| 52-week | High : | 1.91 | Low : | 0.92 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ VANI ] has closed above bottom band by 46.1%. Bollinger Bands are 60.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.43 - 1.44 | 1.44 - 1.45 |
| Low: | 1.35 - 1.36 | 1.36 - 1.37 |
| Close: | 1.37 - 1.38 | 1.38 - 1.39 |
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company that specializes in developing innovative implantable medical devices. The firm aims to address chronic diseases for which current treatments are insufficient or lacking. Its key initiatives include a portfolio of miniature drug implants, designed to ensure consistent and stable therapeutic drug delivery, as well as advanced implantable visual prostheses intended to provide meaningful artificial vision to blind individuals. Vivani Medical is headquartered in Emeryville, California.
Mon, 17 Aug 2026
Vivani Medical posts slide presentation under Reg FD; Exhibit 99.1 attached - TradingView
Sat, 15 Aug 2026
Wall Street Zen Upgrades Vivani Medical (NASDAQ:VANI) to "Hold" - MarketBeat
Fri, 14 Aug 2026
Vivani Medical (NASDAQ: VANI) Completes Full Enrollment In Semaglutide Implant Trial, Strikes Novo Nordisk Deal - foreignpolicyjournal.com
Thu, 13 Aug 2026
Vivani Medical: Q2 Earnings Snapshot - WKYC
Thu, 13 Aug 2026
20 Participants Dosed in Semaglutide Trial; Data Due in November - Stock Titan
Thu, 13 Aug 2026
Vivani Medical (VANI) widens GLP‑1 pipeline, funds runway into Q2 2027 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 86 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 57.9 (%) |
| Held by Institutions | 6.5 (%) |
| Shares Short | 354 (K) |
| Shares Short P.Month | 379 (K) |
| EPS | -0.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.21 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -44.7 % |
| Return on Equity (ttm) | -176.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.32 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -3.46 |
| PEG Ratio | 0 |
| Price to Book value | 6.27 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|